Premium
P4–286: Pharmacology of BAN2401: A monoclonal antibody selective for beta‐amyloid protofibrils
Author(s) -
Swanson Chad,
Kaplow June M.,
Mastroeni Diego,
Rogers Joseph,
Waara Erik Rollman,
Navia Bradford,
Lai Robert,
Logovinsky Veronika,
Möller Christer,
Lannfelt Lars,
Satlin Andrew
Publication year - 2013
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2013.05.1679
Subject(s) - microglia , chemistry , monoclonal antibody , long term potentiation , amyloid beta , pathogenesis , hippocampal formation , pharmacology , antibody , fibril , amyloid (mycology) , biophysics , biochemistry , receptor , neuroscience , pathology , medicine , immunology , peptide , biology , inorganic chemistry , inflammation
its antigen in the brain (stealth antibody). The effect of the clinical candidate, SAR228810, was evaluated in the same model after induction of immunotolerance by transient depletion of CD4+ T lymphocytes. SAR228810 at 10mg/kg/week showed the same level of efficacy as the murineSAR255952. SAR255952 (up to 50 mg/kg/week IV) did not increase brain microhemorrhages and/or microscopic changes in meningeal and cerebral arteries in old APPSLmice. Conversely, brain cortical microhemorrhages or degeneration/necrosis in meningeal and/or cerebral arteries was notedwith 3D6, the murine antibody of bapineuzumab.Conclusions:Based on SAR228810 improved efficay/safety profile, a phase1 single andmultiple dose administration clinical study in AD patientshas been initiated.